Alibaba Health Co-Leads Investment in Yingsheng Bio to Advance Precision Medicine Frontier

Recently, Alibaba Health completed a joint investment in Shandong YingSheng Biotechnology Co., Ltd. (hereinafter referred to as “YingSheng Biology”), a domestic clinical mass spectrometry enterprise. The Zijin Hongyun Fund, co-managed (Co-GP) by Huatai Zijin and Alibaba Health, led this round of financing, which will help YingSheng Biology continue to increase its investments in R&D, market layout, and capacity expansion.

As a cutting-edge innovative technology in the medical field, mass spectrometry boasts advantages such as high sensitivity, high specificity, high accuracy, a wide linear range, and high throughput. It holds immense application potential and scientific value across multiple clinical domains, including clinical biochemistry, clinical immunology, clinical microbiology, and clinical molecular diagnostics, and is regarded as the next technological tipping point in the field of in vitro diagnostics.

“Mass spectrometry is the next powerful tool for precision medicine. Alibaba Health has previously engaged in the research, diagnosis, and treatment of major diseases through internet-based approaches, while simultaneously exploring and strategizing for the future, committed to providing users with precise and convenient healthcare services to help more people improve their quality of life,” said a representative from Alibaba Health.

Founded in 2009, YINGSHENGBIOLOGY is a pioneer in technology development, quality control, and technical services in the field of clinical mass spectrometry in China. It mainly provides clinical customers with comprehensive solutions including pre-treatment, mass spectrometry testing, diagnostic reagents, and mass spectrometry maintenance. The company has established leading gene testing and mass spectrometry testing platforms in China, covering areas such as birth defect screening, disease prevention, and human health services.

In the field of medical devices, mass spectrometry testing has been widely adopted in developed countries in Europe and the United States, with over 400 mass spectrometry-based assays currently serving clinical diagnosis and treatment. In contrast, China’s mass spectrometry industry still lags significantly behind these developed nations, with the majority of the market dominated by foreign brands. As a key core technology, mass spectrometry has drawn considerable attention from the industrial, scientific research, and medical communities. By supporting domestic enterprises to intensify their R&D efforts, the localization of mass spectrometry technology is accelerating, offering promise to resolve critical technological bottlenecks. Notably, YINGSHENGBIOLOGY has launched a one-stop clinical mass spectrometry solution that addresses the five essential elements for the development of clinical mass spectrometry (mass spectrometers + reagents + sample pretreatment + data + services), thereby better supporting disease prevention, screening, diagnosis, and treatment in the era of precision medicine.

The completion of this joint investment is regarded as Alibaba Health’s continued advance into the “frontline” of precision medicine, marking another strategic move in its recent efforts to deploy cutting-edge medical technologies. In March this year, Alibaba Health completed a strategic investment in LinkDoc Technology, a unicorn enterprise in the oncology sector. The two parties will jointly build a comprehensive disease-cycle service platform for cancer patients in China, providing users with precise and convenient services for critical illnesses, thereby enhancing the quality of disease treatment and care.